A 12-week Extension of the Phase III Study (D3820C00004) to Assess the Effect and Safety of NKTR-118 in Patients With Non-cancer-related Pain and Opioid-induced Constipation

NCT01395524 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

302

Enrollment

INDUSTRY

Sponsor class

Conditions

Opioid-Induced Constipation (OIC)

Interventions

DRUG: NKTR-118
DRUG: NKTR-118
DRUG: Placebo

Sponsor

AstraZeneca